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ABSTRACT 
Objective: This work aimed to establish and formulate the gossypin proniosomal gel drug delivery system.  
Methods: Gossypin-loaded proniosomal gels (GPG) was prepared using specific non-ionic surfactants (Spans), followed by particle size (PS), 
entrapment efficiency (percent EE), in vitro, ex-vivo drug release, and in vitro efficacy of Gossypin against human melanoma cells (A-375).  
Results: The results showed that the percentage EE for the GPG is appropriate (81.3 %–95.5 %) and they are Nano-sized (189.3–912.0 nm) and the 
gels diffusion provided the desired sustaining effect for GPG-F7 formulation (75.5 percent). The GPG reported cell viability of 14.9±2.3 percent 
compared with 16.1±1.1 percent for free Gossypin at the maximum dose of 100 μg/ml for A-375 human melanoma cells after 24 hr incubation time. 
No major changes were seen in the percentage EE, PS of GPG after storage for 90 d, in the physical stability report.  
Conclusion: The results obtained suggest that the proniosomal drug delivery system can enhance the flux to the skin and achieve the ideal Gossypin 
sustainability effect. Consequently, the use of proniosomal gel may be advantageous with regard to the topical delivery of Gossypin for melanoma 
treatment management. 
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INTRODUCTION 
The most dangerous diseases among different cancers of the skin are 
melanoma. Cutaneous melanoma accounts for about 3 percent of all 
skin cancers and 75 percent of malignant cancer causes higher 
mortality rates [1]. Chemotherapy, cell therapy, immunotherapy and 
hormone therapy are different cancer treatments, with cancer varying 
from 5-10 % annually [2]. Actinic and solar keratosis was primarily 
seen in skin conditions, and numerous authors reported their 
treatment [3]. Aside from current therapies for skin cancer, there is an 
urgent need for new drug molecules. Although new therapies 
(ipilumab, pembrolizumab and nivolumab) display improved chronic 
responses, the key disadvantage from such therapy effectiveness is the 
severe adverse effects [4, 5]. Phytochemicals are supplied in the 
treatment of low-cost and low-toxicity skin cancer as a dietary 
supplement. The diagnosis of skin cancer now plays a prominent role 
in the delivery of topical drugs [6]. The polyphenolic compound in 
herbal foods is flavonoids. There are 400 different types of organic 
behaviors, such as anti-tumor and anti-inflammatory acts [7]. 
Gossypin belongs to the glucosyl flavone class found in the 
malvaceae family's flora of hibiscus vitofolius [8]. This is water-
soluble due to the existence of glucose moiety [9]. Gossypin (10 and 
100 mg/kg) has been reported for use with apoptosis in the 
treatment of human melanoma (A-375, xenografts) with 
BRAFV600E, which is a mutation of BRAF gene [10] formerly known 
as serine/threonine-protein kinase. It is found to be a new anti-
carcinogenic agent for the treatment of BRAFV600E kinase and 
CDK4 (cycline-dependent kinases) inhibitory melanoma [11]. In 
addition to antioxidant, analgesic and hepatoprotective activities, it 
has a defensive role against beta-amyloid-induced toxicity [12]. The 
growth factor of beta-activated kinase-1-mediated NF (nuclear 
factor) kappaB pathways, penta hydroxylic glucocyle flavone, 
inhibits the apoptosis and subsequently suppresses 
osteoclastogenesis [13, 10]. Gossypin has been confirmed to have 
anti-cancerous papillomas sustained in the rodent model DMBA (7, 
12-dimethylbenz (a) anthracene) [14, 15]. The perfect medicine for 
skin conditions reaches deeper skin layers. The technique involves 
assessing the concentration of medicines in the epidermis and 
dermis in order to ensure an successful distribution [16].  
Localization of drugs improve long-term effectiveness [1]. This 
medicine is encapsulated in a vesicular medication supply to 
enhance the transdermal supply of liposomes, ethosomes, and 
transferosomes [17], but this medicinal substance may become 
unstable because of accumulation, hydrolysis, fusion and 
sedimentation during storage [18]. The delivery mechanisms of 
proniosomes solved vesicular system stability problems. 
Proniosomes structures consisting of non-ionic surfactants forming 
niosomes through water absorption, producing an occlusive state, and 
serving as a potential route of transdermal delivery are considered to 
be semi-strong gel-like composites [19]. The main goal was to explore 
new approaches using non-ionic surfactants using different HLB 
(Hydrophilic-Lipophilic balance) values. The intrinsic properties of 
tensile substances determined by phase transition temperature, 
surfactant form etc. In vitro drugs, particulate scale, ex-vivo skin 
penetration, in vitro cytotoxicity and stability were also studied. 
MATERIALS AND METHODS 
Materials 
Gossypin was supplied as a gift sample from Prof. Ganapaty, 
Principal GIP-GITAM (Deemed to be University, Visakhapatnam, A. P 
(India). Cholesterol procured from Finar chemical laboratory, soya 
lecithin obtained from sigma limited chemicals (Hyderabad, India). 
Span20, Span40, Span60, and Span80 were collected from Molychem 
laboratories, Thane (India). Dialysis membrane (12,000-14,000 M. 
W cut off) was purchased from Himedia Laboratories Pvt. Ltd., 
Mumbai, (India). All other solvents and chemicals were of scientific-
analytical grade. A-375 cells of human melanoma were collected 
from the National centre for cell science, Pune (India). 
Animals 
Swiss albino mice (25±30 gr) 6-8 w old were taken from the disease-
free animal house of the National Institute of Nutrition, Hyderabad 
(India). Animals were kept in groups of four in cages at room 
temperatures between 20 °c and 25 °C and had free access to food 
and water. All research and testing activities have been reviewed 
and approved by the Institutional Animal Ethics Committee 
(IAEC/GIP-1287/GVR-F/2019). 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 13, Issue 1, 2021 
Rajkumar et al. 




Preparation of gossypin proniosomal gel (GPG) 
The proniosomal gel has been prepared with different grades of non-
ionic surfactant, lecithin, and cholesterol using a coacervation 
separation process [20, 21]. The batch amount of gossypin was 
precisely weighed together with surfactant; lecithin and cholesterol 
were mixed with 2.5 ml of ethanol in a wide mouth glass tube. The 
contents are heated in a water bath at 65±3 °C for 5 min. In order to 
achieve transparent dispersion, 1.6 ml pH-7.4 phosphate buffer 
solution was added to the above mix under constant heating 
conditions. The transparent dispersion was cooled until a gel-like 
structure (proniosomal gel) had been formed. During the preparation, 
various grades of spans were used to test their effect on formulation 
characteristics. Different preparations were analysed with varying 
amounts of surfactant and lecithin. Cholesterol is an important factor 
which gives stability and penetrability to the vesicles. The 
compositions produced are listed in (table 1). 
Characterisation of gossypin proniosomal gel (GPG) 
Particle size distribution and zeta potential 
The equipment for the Malvern-zeta sizer (Nano ZS90) was used to 
calculate the average size, size and zeta potential by the dynamic 
light distribution method. The prepared proniosomal gel was 
dispersed up to 0.2 g in 10 ml of the 7.4 pH phosphate buffer 
solution. The prepared solution was tested at a refractive index of 
1,333 for the size and poly dispersibility index (PI) of 25 °C. The PI 
was developed as a measure of homogeneity [22]. PI received as:  
PI =  (Standard Deviation/Vesicle size) 
Small PI values (<0.1) indicate a standardized population, while PI 
values>0.3 are too high. 
Encapsulation efficiency (% EE) 
The prepared proniosomal gel (0.2 gr) has been dispersed with 10 ml 
of pH 7.4 phosphate buffer solution for trapping efficiency. Sonication 
in a bath sonicator for 30 min was subjected to a watery dispersion of 
niosomes [19, 40]. The gossypin containing niosomes has been 
centrifuged for 45 min to separate gossypin at 9000 rpm at 4 °C. The 
supernatant was collected and the concentration of gossypin was 
analysed by UV spectrophotometer at 278 nm from the following 
equation: The proportion of drugs encapsulated was determined:  
% E. E = 1 −  
( Unentrapped drug)
(Total drug)
×  100 
Differential scanning calorimetry (DSC) 
The possible interactions between gossypin and vesicular 
ingredients, based on the thermal properties of a pure drug, were 
evaluated using diamond DSC (Mettler star sw8.10) by Differential 
Scanning Colorimetry (DSC) [23]. A maximum of 50 °C min-1 to 400 
°C min-1 was conducted under nitrogen flow of 25 ml min-1
Fourier transform infrared (FTIR) spectroscopy 
. GPG-7 
was selected with the highest percentage EE, and for a DSC 
evaluation, samples of 4 mg per niosome from gossypin, span 60, 
empty and drug-loaded proniosomes were sent. The precisely 
weighed sample sum was crimped in the DSC aluminium pot and 
samples were analysed at a heating rate of 10 °C/min at a 
temperature of 400 °C. 
Gossiping powder was pressed into a pellet al. ong with KBr 
(potassium bromide) using a hydraulic press. GPG-7 final optimized 
formulation IR spectrum of drug gossypin was tested on Fourier 
transform infrared spectroscopy (FTIR) in the 4000-400 cmˉ1
Transmission electron microscope 
 wave 
range [23]. 
The morphological examination of the prepared niosomal gel was 
analysed with TEM. Hydrating the proniosome gel (0.2 gr) with 10 
ml phosphate buffer solution (pH 7.4) was used to prepare the 
sample. A scatter droplet was placed on a carbon-coated copper grid 
and left to stay for around 1 minute on the carbon substrate. The 
dispersion was also extracted with a little Whatman paper. A 1% 
phosphorous tungsten acid solution was applied and again, an 
excess solution was separated by a tip of whatman paper. Samples 
were allowed to dry for 10 min at room temperature for inspection 
after being labelled [14]. 
In vitro drug release study 
Gossypin release from Proniosomal gel was determined by the use of 
a technique of dialysis membrane diffusion [24, 25]. An open glass 
tube with a diameter of 4,153 cm2
Ex-vivo skin permeation and drug retention study 
 and an effective length of 8 cm has 
been closed one end with the dialysis membrane previously soaked 
overnight in the pH phosphate buffer 7.4, which acts as a rate-
limiting membrane. The glass tube toward the donor compartment 
was filled with 5 mg gel formulation. During a beaker that contains 
40 ml of pH 7.4 phosphate buffer, the glass tube was positioned 
which acts as a receptor compartment medium. The entire assembly 
was set in such a way that the lower end of the membrane-
containing channel, which had just met the surface of the diffusion 
medium after having gel (1-2 mm deep). The receptor department 
temperature was held at 37±2 °C, and thus the medium was agitated 
at 100 rpm speed using a 24 h magnetic stirrer. Samples were 
obtained at different periods of time (1, 2, 3, 4, 5, 6, 7, 8, 12, 18 and 
24 h). Aliquots of 5 ml samples were regularly removed and 
replaced by an equal amount to maintain sink conditions. Using a 
validated analytical approach (n=3), the samples obtained were 
analysed. 
The research analysis was carried out after approval by the ethical 
committee of the institutional animals (approval no: IAEC/GIP-
1287/GVR-F/2019). Swiss albino mice (25±30 gr) were used in the 
study, the animals were housed in separate cages and held under 
controlled temperature conditions and the rats had free access to 
water and food before they were sacrificed in compliance with the 
guidelines for skin harvesting Euthanasia and carcass [14]. Using 
extra amount of anaesthetic ether, the rats were sacrificed. Once the 
skin was surgically extracted, hair on the dorsal side was cut with a 
hair clipper taking strict precautions not to damage the skin. A heat 
separation technique was used to prepare the epidermis [22, 26]. It 
involved soaking up the whole abdominal skin in the water at 60 °C 
for 45 seconds, followed by thorough removal of the epidermis. 
Dried water, wrapped in aluminium foil and held until further use 
at-20 °C [27] (used within 2 w of preparation). Ex-Vivo permeation 
experiments were performed using unjacketed Franz vertical 
diffusion cells with a 4,153 cm2 diffusional surface area and 20 ml of 
the receptor cell length. The skin was brought to room temperature 
and placed between the Franz diffusion cell's donor-receiver 
compartments, where the stratum corneum side faced the donor 
compartment [21]. The skin was allowed to stabilize for 1 hr before 
dosing, and a formulation equivalent to 5 mg of gossypin was 
injected on the skin's dorsal side. The receptor compartment 
containing pH-7.4 phosphate buffer (containing 0.02 percent w/v of 
ethanol to retard microbial growth) was kept under continuous 
stirring up to 24 h at 32 °C on the skin surface [28]. At 300 rpm, the 
receiver compartment was continuously stirred [29]. The donor 
chamber and the sampling port were covered with a lid to avoid 
evaporation during the test. Aliquots of 5 ml were regularly removed 
at different time intervals (1, 2, 3, 4, 5, 6, 7, 8, 12, 18 and 24 h) and 
replaced by equivalent volume to preserve the receptor’s constant 
phase volume. Same test with pure drug was performed. The 
samples were diluted sufficiently and the amount of the drug was 
measured at 278 nm (n=3) using the UV-Visible spectrophotometer. 
The substance stored in the skin was calculated with a minor change 
following the procedure [30]. The experiment was performed after 
the permeation tests were done (24 h) [31]. The gel present on the 
compartment cell was removed, washed with PBS and methanol (1:1 
v/v) and the UV absorbance was set at 278 nm. The residual skin 
was sliced into tiny bits to determine the amount of drug in the 
viable skin (epidermis and dermis). They were poured into a conical 
flask containing 50 ml of PBS (7.4 pH) and methanol (1:1 v/v), put 
on for 48 h to the rotary shaker. The solution was then filtered using 
UV Visible Spectrophotometer at 278 nm, and the amount of drug 
extracted from the skin sample was determined. 
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Skin permeation data analysis  
The cumulative amount of material that was permeated into a unit 
region of the skin was plotted as a function of time [32-34]. 
Flux  
The Steady-State Flux was determined using slope of the graph. 
Jss =  (dQ/dt) ∗ (1/A) 
Where Jss = Steady State Flux (µg/cm2
Permeability coefficient (Kp)  
/hr), A=Surface area, dQ/dt = 
Cumulative quantity permeated per unit area per unit time. 
The following equation was used to calculate the coefficient of 
permeability, which describes the relation between the flux and the 
initial drug charge [35]. 
Kp =  Jss Cdonar⁄  
Where, Kp =Permeability co efficient (cm/hr), Jss = transdermal flux, 
C= Initial concentration of drug donor compartment [36]. 
In vitro cytotoxicity study of gossypin proniosomal gel (GPG) 
In vitro cytotoxicity for free drugs and drug-charged gels was 
estimated by 3-(4, 5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium 
bromide (MTT) assay. Briefly, A-375 human melanoma cells were 
seeded into 96-well plates in 100 μL Dulbecco Modified Eagle 
Medium at a density of 1 X 104 cells per well and incubated 
overnight. Cells were then exposed to a sequence of free drugs and 
drug-loaded gels at a change in the strength of 0-100 μg/ml for 24 h, 
correspondingly using A-375 human melanoma cells as a trigger 
untreated. After the incubation period, the media was removed and 
the cells were treated with an MTT solution (50 μL; 5 mg/ml) in the 
Dulbecco Modified Eagle Medium serum-free for 4 h. The solution 
has been removed and 150 μL of dimethyl sulfoxide (DMSO) has 
been added to each well. The plate was previously incubated at room 
temperature for 30 min. Absorption intensity was measured using a 
590 nm UV-Vis spectrophotometer with a reference wavelength of 
620 nm. The following equation expressed the viability of cells [34]. 
Cell viability (%) = Absorbance of
sample
Absorbance
of control × 100 
Stability studies  
The preparations were packed in glass vials undergoing stability 
tests at accelerated storage conditions (40 °C±2 °C), room 
temperature (25±2 °C) and in a refrigerator (2-8 °C) for three 
months. Samples were evaluated for entrapment efficiency and size 
at definite intervals (1,2 and 3 mo). Formulations that retain 
entrapping capacity for 3 mo are known as long-lasting 
formulations. Samples were taken and hydrated with phosphate-
buffered saline solution (pH 7.4) and analyzed under an optical 
microscope for any evidence of product crystallization. Additionally, 
the samples were percentage-tested for particle size and gossypin 
retention [35, 36, 41]. 
RESULTS AND DISCUSSION 
Preparation of gossypin proniosomal gel (5-FUPG) 
In the present investigation, proniosomal gel-loaded gossypin was 
prepared using non-ionic surfactants using coacervation techniques. 
Prepared niosomes were evaluated for particle size, shape, 
entrapment efficacy, in vitro, ex-vivo drug release and efficacy 
against human melanoma cells. (table 1) Shown Composition of 1% 
gossypin proniosomal gel (GPG) formulations. 
 
Table 1: Composition of 1% gossypin proniosomal gel (GPG) formulations 
Formulation Gossypin (mg) Span20 (mg) Span40 (mg) Span60 (mg) Span80 (mg) Lecithin (mg) Cholesterol (mg) 
GPG-1 10 234.5 - - - 703.5 52 
GPG-2 10 - 234.5 - - 703.5 52 
GPG-3 10 - - 234.5 - 703.5 52 
GPG-4 10 - - - 234.5 703.5 52 
GPG-5 10 469 - - - 469 52 
GPG-6 10 - 469 - - 469 52 
GPG-7 10 - - 469 - 469 52 
GPG-8 10 - - - 469 469 52 
GPG-9 10 703.5 - - - 234.5 52 
GPG-10 10 - 703.5 - - 234.5 52 
GPG-11 10 - - 703.5 - 234.5 52 
GPG-12 10 - - - 703.5 234.5 52 
 
Particle size distribution and zeta potential 
The results of newly reconstituted dispersions of gossypin 
proniosomal developed formulation are shown in table 2. All 
formulations were found in the nanoscale range between 189.3 nm 
(GPG-7) and 921.9 nm (GPG-9) with a low polydispersity index 
ranging from 0.108 (GPG-6) to 0.199 (GPG-9), indicating 
homogenous dispersion. In addition, the measured zeta potential 
values of the formulated proniosomes were negatively charged, with 
zeta potential loads ranging from-22.65 mV to-55.52 mV showing 
good physical stability of the niosomal dispersion.  
Spans are well-known non-ionic surfactants used as vesicles for the 
treatment of niosomes and proniosomes. When assessing the 
different grades of Spans, e. g. 20, 40, 60 or 80, it was found that 
their nature significantly affected the final vesicle sizes [9]. 
 
Table 2: Particle size, polydispespersity index and zeta potential analyses of gossypin proniosomal gels 
Formulation Particle size(nm) Polydispersity index Zetapotential (mV) 
GPG-1 912.0 0.124 -29.54 
GPG-2 657.3 0.186 -35.86 
GPG-3 224.6 0.136 -47.45 
GPG-4 554.6 0.137 -22.65 
GPG-5 456.2 0.121 -49.82 
GPG-6 758.6 0.108 -31.21 
GPG-7 189.3 0.186 -55.52 
GPG-8 652.4 0.186 -36.21 
GPG-9 921.9 0.199 -27.93 
GPG-10 463.8 0.154 -32.42 
GPG-11 235.4 0.178 -50.81 
GPG-12 545.1 0.185 -25.80 
Data expressed mean±SD (n= 3) 
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Encapsulation efficiency (% EE) 
In the design of vesicular formulations, encapsulation efficiency is one 
of the essential parameters. The effectiveness of vesicle encapsulation 
depends on the type and amount of surfactant used in bilayer 
formation and on the amount of cholesterol and lecithin [37]. 
Efficiency of encapsulation tests of formulations are shown in table 4. 
For formulations prepared with Span 60, higher encapsulation efficacy 
than with Span 20, Span 40 and Span 80 were observed. Span 60’s 
longest saturated alkyl chain shows a higher phase transition 
temperature (Tc), which represents the percentage of encapsulation 
efficiency. For Span 60 formulations of Span 20, 40 and 80, the vesicle 
size was also less. The literature also indicates that, as hydrophobicity 
of the monomer of surfactants increases, it decreases the size of the 
vesicle. Both span forms are of the same head group, but alkyl chains 
are distinct. The length of the alkyl chain increases the encapsulation 
efficiency. The order of encapsulation efficiency was observed for 
different grades of Span 60 (C18)>Spain 40(C16) Spain 60 and 80 have 
identical head classes, but Spain 80 has an alkyl chain which is 
unsaturated. Span 80 is the lowest in the comparison spans (16 °C for 
span20, 42 °C for span 40, and 53 °C for span 60). Spain 80 is of the 
highest transition temperature, Tc=12 °C). The highest transition 
temperature in the process in Span causes the medicine to be 
entrapped the lowest and vice versa. In the range of 81.3% to 94.4% 
and in the intermediate stage of the surfactant concentration EE, 
specifically, was found to be within the range of 81.4% to 95.5%. 
Whereas the surfactant EE level was found to be between 81.3% and 
91.8% at a higher level. The lower, mid and higher levels of lecithin 
content were shown to increase gradually in EE, which is usually 
added to improve the stability of the formulation. 
Differential scanning calorimetry (DSC) 
Fig. 1(a) and 1(b) below display gossypin and drug-loaded niosomes 
with DSC thermograms. Gossypin exhibited an endothermic peak 
corresponding to their melting temperatures at 228.5 °C, 
respectively. Proniosomal DSC thermogram showed a high 
endothermal peak at 129 °C, suggesting the association of span 60, 
cholesterol, and lecithin molecules. This supports double-layer 
structure of the vesicle. No gossypin peak in the drug-loaded 
formulation has been identified, suggesting the amorphous nature of 
the drug. This observed finding may be due to the complete 
solubility of the drug in the vesicles and may account for the 
increased entanglement in formulations of gossypin. 
  
 
Fig. 1: a) DSC thermograms of gossypin 
 
 
Fig. 1: (b) DSC thermograms of GPG-7 
 
Fourier transforms infrared (FTIR) spectroscopy 
FTIR study of the selected formulation (GPG-7) prepared with the non-
ionic surfactant, i.e. Span 60, soya lecithin, cholesterol and drug. The 
spectrum peak points of the formulation were similar to that of pure 
gossypin, which clearly indicates that there is no drug or excipient 
interaction. The FTIR spectra of pure gossypin and the formulation 
were given in the following section. FTIR images have been shown in 
(fig. 2 and table 4.) describes the FTIR spectrum of peak points of the 
pure drug and the prepared formulation (GPG-F7). 
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Fig. 2: (a). FTIR spectrum of gossypin 
 
 
Fig. 4: (b). FTIR spectrum of GPG-7 
 
Table 3: Describes the FTIR spectrum peak points of pure Gossypin and the prepared formulation (GPG-7) 
Pure gossypin Gossypin (GPG-7) 
Wavenumber cm-1 
3524(alc. O-H) 3525 
1635(C=O) 1637 
1600(C-C) 1602 
2982(SP3 2978 C-H) 
3381(phenolic O-H) 3385 
1502(Sp2 1498 C-H) 
 
 
Fig. 3: TEM image of GPG-7 
 
Transmission electron microscope 
(fig. 3) Illustrates the presence and surface morphology of vesicles 
following hydration with distilled water for GPG-7. As a fiddle with a 
smooth surface, the inspected vesicles appeared well known, round fit. 
In vitro drug release study 
The results of the in vitro release of gossypin from different 
formulations are shown in (table 4 and (fig. 4). The combination of 
gossypin in all proniosomal formulations showed a noteworthy 
slower release profile compared to the control of gossypin release in 
12 h. The initial release was expected to be rapid due to gossypin 
disorption from the surface of the proniosomes. Controlled slow 
release was expected due to the diffusion of the swollen 
proniosomal bilayer. Proniosomes composed of Span60 indicated a 
higher release rate than those prepared for the use of non-ionic 
surfactants, Span40, Spam20 and Span80. Span20 and Span80 have 
lower phase transition temperatures and a less penetrable rigid 
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bilayer structure than Span60 and Span40, which frames a 
progressively porous liquid bilayer [9, 26]. Expanding the lecithin 
content from 234.5 to 703.5 mg resulted in an increasingly 
unblemished lipid bilayer as an obstruction to drug release. 
Increased concentration of lecithin decreased leakage and 
permeability of gossypin, delayed release of trapped drugs from the 
vesicles and resulted in a noteworthy slow release profile. In 
addition, the best release profile of the different formulations was 
observed using Span60 with a mean concentration of 469 mg. 
Formulation F7, containing Span60 as a surfactant, showed more in 
vitro release of drugs, i.e. 75.5 percent of all surfactants. The release 
rate was also dependent on noisy membrane fluidity as a function of 
either acyl chain length and saturation or cholesterol content. The 
optimized formula F7 based on Span60 was added to stability based 
on in vitro characterizations (table 6). When comparing the release 
outlines of the control formulation with that of the proniosomal 
formulation, a significant delay in drug release was seen in 
proniosomes. Long-term treatment with prolonged-release patterns 
was required to treat the targeted site drug delivery, in particular, 
the treatment of skin cancer of the type of topical disease [34]. 
Release studies were evaluated for release of the kinetic mechanism 
using Zero order, First order, Higuchi, Korsmeyer-Peppas models. 
Kinetic analysis of all formulation profiles followed a diffusion-
controlled mechanism with an initial rapid-release phase followed 
by slower releases. Release of the GPG-7 batch, fitted to the Higuchi 
matrix equation, showing a high R2 value (0.98015). It can therefore, 
be determined that the release of gossypin from the proniosomal gel 
formulation was based on the diffusion-controlled mechanism of the 
Higuchi matrix. As a result, the release of the drug from this matrix 
may have been affected by the diffusion mechanism. 
 
 
Fig. 4: In vitro drug release of proniosomal gels (GPG-1 to GPG-12) and control, data expressed mean±SD (n= 𝟑) 
 
Ex-vivo skin permeation and drug retention study  
Proniosomes that permeates through the skin to form niosomal 
vesicles should be hydrated before the drug is released. Many 
mechanisms may explain the ability of niosomes to modulate drug 
transmission through the skin, including (i) adsorption and fusion of 
niosomes to the skin surface that will promote drug permeation, (ii) 
vesicles act as penetration enhancers to minimize the barrier 
properties of stratum corneum, and (iii) niosomal lipid bilayers act 
as a drug membrane barrier. Interestingly, no lag step could be 
detected and gossypin could be detected in the receptor medium 
within one hour, suggesting that all processes (water permeation 
from the receptor compartment to the skin, proniosomal conversion 
to niosomes, gossypin release from the reconstituted niosomes and 
its permeation) occurred quite quickly [38, 39]. 
Gossypin major permeation occurs only when the drug was released 
from the niosomes and formed with skin fluid after hydration of the 
proniosomal gel. The penetration data obtained from different 
proniosomal formulations based on surfactants compared with an 
equivalent concentration of the drug regulation. The findings 
showed that, in the first cycle, the amount of drug permeated 
through the skin was shown higher. Penetration rate was sluggish 
afterward for all formulations of the vesicles. Results shown in table 
4 and fig. 5 seem to indicate that proniosomal formulations 
significantly delayed the penetration of the drug through the skin. 
Proniosomes were identified with a major increase in drug retention 
in the skin as they consisted of cholesterol, lecithin and a surfactant. 
The optimized formulation GPG-7 (span 60) showed a 65.5 percent 
higher drug release than the other formulations with Span 20, Span 
40 and Span 80. 
 
 
Fig. 5: Ex-vivo drug release of proniosomal gels (GPG-1 to GPG-12) and control, data expressed mean±SD (n= 𝟑) 
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Table 4: Entrapment efficiency, in vitro and ex-vivo percentage cumulative drug release of gossypin proniosomal gels 
Formulation Entrapment efficiency 
(%) 
In vitro percentage cumulative drug release 
(24 h) (%) 
Ex-vivo percentage cumulative drug release 
(24 h) (%) 
GPG-1 83.2 69.1 58.9 
GPG-2 88.3 70.2 60.8 
GPG-3 94.4 73.8 63.2 
GPG-4 81.3 66.9 56.9 
GPG-5 82.9 69.8 58.4 
GPG-6 90.6 71.2 61.4 
GPG-7 95.5 75.5 65.5 
GPG-8 81.4 66.2 56.2 
GPG-9 82.2 67.9 57.9 
GPG-10 91.8 70.4 62.8 
GPG-11 90.2 70.8 61.3 
GPG-12 81.3 65.8 55.7 
Data expressed in mean±SD (n=3) 
 
Skin permeation data analysis 
Even the parameters of proniosomal skin permeation, as well as drug 
suspension, were measured at a medication concentration equivalent. 
The flux value obtained from the GPG-7 proniosomal gel (20.3μg/cm2/h) 
was found to be 2.7 times higher than that of the suspension drug 
(7.6μg/cm2/
 
h) (table 5). Gossypin's comparatively low suspensive skin 
permeability was attributed to its lower aqueous solubility, while the 
high proniosomal permeability resulted in improved penetration of the 
gossypin surface. Better transdermal flux without a lag step of the 
proniosomal gel may result from one or more wing mechanisms as 
previously mentioned, i.e. increased gossypin solubility, high association 
of drugs with vesicle bilayers, increased vesicle partitioning into the 
stratum corneum, and elasticity of the vesicle membranes [35]. 
Table 5: Permeation parameters of drug dispersion and proniosomal formulation 
Formulation Gossypin permeated through skin at 24 h (%) Total gossypin accumulated to skin (%) Flux (μg/cm2/h) 
GPG-5 11.6 19.8 14.5 
GPG-6 12.5 22.6 17.6 
GPG-7 16.3 35.3 20.3 
GPG-8 14.7 29.3 12.5 
Drug dispersion 56.3 15.5 7.6 
Data expressed in mean±SD (n=3) 
 
In vitro cytotoxicity study of gossypin proniosomal gel (GPG) 
The in vitro cytotoxicity of drug-carried gels has been tested in 
human melanoma cell lines A-375. Gels without active substances 
with the same concentrations of polymers as drug-induced gels were 
used as control. Cells were incubated in the presence of free-drug 
and drug-loaded gels for 24 h and were tested with the MTT assay. 
After incubation with various formulations, the viability of A-375 
human melanoma cells was shown in fig. 6. Gossypin loaded gels 
(GPG) had cell practicality of 14.9±2.3% compared to 16.1±1.1%. 
The formulations are incubated 24 h long and display higher 
cytotoxicity in human melanoma cells A-375. We have tried 
medication-free gels to show that the cytotoxic effect of GPG gel is 
expected because of the toxicity of GPG for its effect on cell viability. 




Fig. 6: In vitro cell viability data of GPG loaded gel and free GPG in A-375 human melanoma cell culture mean±SD(n=3) 
 
Stability studies  
As can be seen from the tests, gossypin flux from the vesicles may be 
due to a change in the surfactant and lipid phase at 40 °C (table 6). 
Be that as it may, there was no significant difference in vesicular size 
or entrapment efficiency (EE) formulations when they were 
removed after 90 d at 2-8 °C and 25±2 °C. To know the stability of 
optimised formulation after stability studies, a further similar 
cytotoxicity study was performed, which indicates that the 
formulation has no significant difference of cytotoxic effect against 
A-375 human cell lines was observed. 
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Table 6: Stability study of GPG-7 
Storage 
time (days) 
2–8 °C 25±2 °C 40 °C±2 °C 
Vesicle size (nm)  EE (%) Vesicle size (nm) EE (%) Vesicle size (nm)  EE (%) 
0 189.3 95.5 189.3 95.5 189.3 95.5 
30 189.2 95.2 189.0 95.1 186.2 94.0 
60 189.0 94.8 189.2 95.0 186.5 92.1 
90 188.9 94.6 189.0 95.2 186.0 91.3 
Data expressed in mean±SD (n=3) 
 
CONCLUSION 
Surface morphology showed that the vesicles were nearly circular 
and clearly visible with sharp limits and large internal aqueous 
space. The test results showed that the EE percentage of prepared 
gossypin proniosomal gels is adequate (81.3 percent–95.5 percent) 
and they are Nano-sized (189.3–912.0 nm), and the gels dispersion 
gave the ideal continuing effect. Formulation GPG-7, containing the 
Span60 as a surfactant suggested a more prominent in vitro drug 
release, i.e. 75.5% of each surfactant. The formulation GPG-7 (mid-
level Span 60) displayed 65.5 percent higher ex-vivo drug releases 
than other formulations with Span 20, Span 40 and Span 80. Gossypin 
loaded gels (GPG) showed 14.9±2.3 percent cell viability as compared 
to 16.1±1.1 percent non-Gossypin's most significant GPG dose of 100 
μg/ml after 24h incubation for A-375 human melanoma cells. There 
was no significant improvement in the vesicular size or 
entrapment efficiency (percent EE) of formulations when stored at 2-8 
°C and 25±2 °C for 90 d. This study demonstrated the reasonableness 
of proniosomal gel in achieving the ideal sustainability effect for 
gossypin's topical conveyance for melanoma therapy. The 
proniosomal gel improved both in vitro skin permeation and Gossypin 
deposition. It was shown to be skin-free and capable of holding 
Gossypin in the skin's deeper layers for an all-inclusive time. The 
findings also clearly defined that the Gossypin loaded proniosomal gel 
can be a good carrier option for transporting the drug through skin 
layers. More studies are necessary to ensure the long-term reliability 
of Gossypin loaded proniosomal gel and the absence of cytotoxicity on 
the various organs to use this carrier may be used to treat skin 
malignant development. Our findings can open the conceivable results 
for GPG topical delivery to treat skin-malignant tissues. 
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